BioSpace News Archive

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 4,532,772 common shares at a purchase price of US$2.77575 per common share in a registered direct offering (the “Offering”) priced at-the-market under the Nasdaq Capital Market (the “Nasdaq”) rules for ag

Israeli startup PulseNmore today announced the launch of its flagship handheld tele-ultrasound device that enables pregnant women to perform at-home ultrasound scans, and receive feedback from a physician or sonographer, limiting the need for hospital and doctor visits during COVID-19 and beyond.

Thermo Fisher Scientific continues to expand its response to the COVID-19 pandemic, developing a new serological assay targeted towards transplant candidates and recipients that can detect antibodies directed against COVID-19 (SA

BVI, the fastest-growing diversified company in ophthalmology, has partnered with Haywood Vocational Opportunities to provide isolation gowns to US healthcare workers on the front lines of the pandemic effort.

The high throughput test will be available in the Fall with next-day turnaround time and will enable Helix to scale its capacity to 100,000 tests per day

- Highly experienced business development executive, Alex Monteith, named as Senior Vice President and Chief Business Officer - Qwo™ (collagenase clostridium histolyticum-aaes) approved by FDA for treatment of cellulite - Patient dosing initiated in clinical trials for XIAFLEX® in both plantar fibromatosis and adhesive capsulitis

Werewolf Therapeutics, Inc., an oncology biotherapeutics company developing next-generation, transformative cancer therapeutics, today announced the appointment of Ellen Lubman to the company’s newly created position of Chief Business Officer. In this role, Ms. Lubman will oversee corporate and business development, portfolio st

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect.

Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the second quarter ended June 30, 2020 and provided a business update.

Early Interim Data from Registrational Phase 2 TRIDENT-1 Study of Lead Drug Candidate Repotrectinib Anticipated in Third Quarter Four Clinical Studies of Three Drug Candidates Ongoing; Early Interim TPX-0022 Data Anticipated in Fourth Quarter Cash, Cash Equivalents, and Marketable Securities of $710 Million Expected to Fund Current Operations into 2023 SAN DIEGO, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology c